On-demand recording and key takeaway available: Insilico introduces generative AI platform enhancements across drug discovery stages in Pharma.ai summer updates webinar

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently hosted its latest Pharma.ai summer updates webinar, the second event in the Insilico quarterly platform launch series initiated in 2025. With brand-new features and functional updates announced, we were excited to welcome an online audience of 250+ attendees ranging from researchers, lecturers, biotech and pharmaceutical leaders, from over 45 countries. For those who missed the live webinar, the on-demand recording is now available on request through the registration link here.

 

Below are some highlights from the Summer Pharma.ai platform updates:

 

Generative Biologics, the AI-empowered platform for biologics generation and optimization

• Candidate production with higher contact numbers and lower ΔG (binding free energy): 

This new generative model takes a diffusion-based approach for generating antibody scaffolds and sequences, allowing conditioning on specific frameworks for customized designs.

• Retrieve and visualize protein structures directly from the RCSB database:

Type the protein PDB code of interest, and the Generative Biologics platform will automatically upload the PDB ID and title, including the experiment method and resolution, and pre-process the file..

• Updated results page with more details and better visualization:

The results page now displays detailed non-covalent interactions (e.g., hydrogen bonds, stacking interactions), includes filtering and sorting options, and visualizes selected interaction types using dashed lines.

• More powerful peptide library screening function based on built-in templates:

Screen peptide libraries against an existing template, with point mutation analyses and comparison with original templates enabled.

 

Chemistry42, the generative chemistry platform combining AI flexibility and physics-based precision

• Alchemistry 2.0 - A physics-based module with an increase of up to fourfold in the speed and improved  accuracy:

Version 2.0 has an enhanced architecture for scalability and efficient GPU resource usage, demonstrating strong performance across various target types (enzymes, GPCRs, etc).

• Updated interface with more information:

Visualization and the ability to download the molecular dynamics are now available in version 2.0.

 

PandaOmics, a cloud-based omics analysis platform generating biological insights with AI

• New functions to streamline research and development:

Duplicate and customize curated meta-analyses, and upload multi-entry data for detailed sample analysis。

• Safer environments and easier sharing:

Virtual Private Cloud (VPC) and Single Sign-On (SSO) for enhanced data security and scalability, and knowledge graph export for usage in reports or manuscripts.

 

DORA, your advanced AI-driven research assistant, is transforming biomedical document production

• Open-source release with paid versions tailored for specific user groups:

Planned community open-source release along with SaaS and enterprise editions offering various access and deployment options.

 

PreciousGPT, multimodal transformers for omics data and living system simulation

• Free access enabled for multiple aging clock through open Python library:

Researchers can now access dozens of aging clocks mentioned in publications from Harvard, Oxford, the University of Connecticut and Insilico Medicine, along with ipf-P3GPT for studying the aging process in fibrotic diseases.

 

In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico has been integrating technical breakthroughs into the Pharma.AI suite, a generative AI-powered solution spanning biology, chemistry, medicine development, and science research. Since its inception in 2014, Insilico has published over 200 peer-reviewed papers and has held more than 600 patents and patent applications.

 

About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico is extending the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. 

For more information, please visit www.insilico.com.

---

---